Search research articles
Contact Us
Filters
Showing results (71-80 of 78) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 78 results.
The Journal of Clinical Investigation
|
May 1, 2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
Alvaro Lopez-Janeiro, José González-Gomariz, Fadi Issa, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitors
Thomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Cancer Research Communications
|
February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Neuro-Oncology Advances
|
August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma
James R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Science Translational Medicine
|
October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Iván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
Cancer Discovery
|
February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Isil Altintas, et al.
Nature
|
July 3, 2024
Author Correction: Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Kristen A Baltgalvis, Kelsey N Lamb, Kent T Symons, et al.
Nature
|
April 24, 2024
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Kristen A Baltgalvis, Kelsey N Lamb, Kent T Symons, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 78) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 78 results.
The Journal of Clinical Investigation
|
May 1, 2026
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
Alvaro Lopez-Janeiro, José González-Gomariz, Fadi Issa, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitors
Thomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Cancer Research Communications
|
February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Neuro-Oncology Advances
|
August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma
James R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Science Translational Medicine
|
October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Iván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
Cancer Discovery
|
February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Isil Altintas, et al.
Nature
|
July 3, 2024
Author Correction: Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Kristen A Baltgalvis, Kelsey N Lamb, Kent T Symons, et al.
Nature
|
April 24, 2024
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Kristen A Baltgalvis, Kelsey N Lamb, Kent T Symons, et al.
Page
of 8